| Name | Title | Contact Details |
|---|
BetterNight’s platform integrates a comprehensive sleep apnea solution including screening, testing, telemedicine, therapy and remote patient monitoring. This comprehensive platform is unique in the market providing clients the opportunity to ...
Orlando Senior Health Network is a network of companies that provides a broad range of residential living options, home care and rehabilitation services, plus pharmaceutical and medical equipment offerings, designed to improve the quality of life for s...
Soka Services LLC is a Pontiac, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
AIM Specialty Health® provides clinical solutions that drive appropriate, safe, and affordable care. Serving more than 50 million members across 50 states, D.C. and US territories, AIM promotes optimal care through use of evidence-based clinical guidelines and real-time decision support for both providers and their patients. The AIM platform delivers significant cost of care savings across an expanding set of clinical domains including radiology, cardiology, oncology, specialty drugs, sleep medicine, musculoskeletal, pain management, and genetic testing. AIM is a wholly-owned subsidiary of Anthem, Inc. (ANTM).